GLP‑1s: organ benefits vs muscle risk
Coverage this week notes GLP‑1 drugs can offer benefits to the liver, heart muscle and blood vessels even when they don’t produce large weight losses. (cnn.com) At the same time, fitness reporting warns users risk losing muscle mass unless they keep up resistance training and prioritize protein, and outlets say many patients quit and later restart these medicines while some states are rolling back Medicaid coverage. ( )
Glucagon-like peptide 1 drugs were built to lower blood sugar and curb appetite, but new research and recent trials show they can help the liver, heart, and blood vessels even when weight loss is modest. (eurekalert.org, nejm.org) In a study released April 14, 2026, researchers at Sinai Health in Toronto said semaglutide acted directly on liver sinusoidal endothelial cells, a layer of cells that lines tiny liver blood vessels, and improved liver function independent of weight loss. (eurekalert.org, medicalxpress.com) That finding lands after larger clinical trials had already linked semaglutide to organ-level gains. In the SELECT trial published in 2023, weekly semaglutide cut major cardiovascular events in adults with overweight or obesity and prior cardiovascular disease but no diabetes; in a 2025 phase 3 trial, semaglutide also improved metabolic dysfunction-associated steatohepatitis, a severe fatty liver disease, in adults with stage 2 or 3 fibrosis. (nejm.org, nejm.org) The same drugs can also shrink lean tissue along with fat. Fitness and health coverage this month said people taking glucagon-like peptide 1 medicines risk losing muscle mass unless they keep up resistance training and eat enough protein while appetite is suppressed. (yahoo.com, health.com, health.usnews.com) That tradeoff has become more visible as use has spread beyond diabetes care into long-term obesity treatment. A recent review in The New England Journal of Medicine said these medicines improve outcomes in cardiovascular, kidney, liver, arthritis, and sleep apnea disorders, with some effects partly independent of the amount of weight lost. (nejm.org, pmc.ncbi.nlm.nih.gov) The practical problem is that many patients do not stay on them continuously. A KPBS report published April 15 said a majority of people who start these obesity and diabetes medicines also quit them and plan to restart, even though research has not yet pinned down the health effects of cycling on and off treatment. (kpbs.org, usatoday.com) Coverage is also getting tighter as demand and costs rise. Kaiser Family Foundation said Medicaid must cover most Food and Drug Administration approved drugs, but federal law lets states choose whether to cover weight-loss drugs, and The Guardian reported April 14 that some states and cities that had covered glucagon-like peptide 1 medicines for weight loss are now pulling back. (kff.org, politomix.com) Doctors and trainers are pushing the same basic advice while the evidence and coverage rules keep shifting: treat these medicines as part of a longer plan, not a short sprint, and protect muscle with strength work and protein while monitoring what happens off the scale. (health.usnews.com, kpbs.org)
